<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89184">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091752</url>
  </required_header>
  <id_info>
    <org_study_id>CINC424A2407</org_study_id>
    <nct_id>NCT02091752</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)</brief_title>
  <official_title>The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Austria: AGES (Bundesamt für Sicherheit im Gesundheitswesen)</authority>
    <authority>Brazil: ANVISA - Agência Nacional de Vigilância Sanitária</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Germany: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Italy: AIFA (Agenzia Italiana del Farmaco)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after
      treatment interruption due to loss of response and/or adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on reduction in spleen volume of at least 20% from baseline, by Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients achieving ≥20% reduction from baseline in spleen volume by Week 24 after re-treatment with ruxolitinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on reduction in spleen volume of at least 35% from baseline, by Week 24</measure>
    <time_frame>By Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients achieving ≥35% reduction from baseline in spleen volume by Week 24 after re-treatment with ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on reduction in spleen length of at least 25% and 50% respectively, from baseline, by Week 24</measure>
    <time_frame>By Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients achieving ≥25% and ≥50% reduction respectively, from baseline, in spleen length by Week 24 after re-treatment with ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on reduction in spleen volume and length over time</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in spleen length as well as in spleen volume from baseline to each visit where measured after re-treatment with ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety after re-treatment with ruxolitinib</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be assessed by monitoring the frequency, duration and severity of Adverse Events, and evaluating changes in vital signs, electrocardiograms (ECGs), serum chemistry, hematology and urinalysis results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on reduction in MPN-SAF TSS of at least 25% and 50% respectively, from baseline, by Week 24</measure>
    <time_frame>By Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients achieving ≥25% and ≥50% reduction respectively, from baseline in total symptom score (MPN-SAF TSS) by Week 24 after re-treatment with ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on reduction in MPN-SAF TSS over time</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in MPN-SAF TSS from baseline to each visit where measured after re-treatment with ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on Patient Global Impression of Change (PGIC)</measure>
    <time_frame>By Week 1 to Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>PGIC at each visit where measured after retreatment with ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of re-treatment with ruxolitinib on EORTC QLQ-C30 and EQ-5D-5L</measure>
    <time_frame>At Day 1, Week 8, Week 12, Week 16, Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in EORTC QLQ-C30 and EQ-5 D-5L scores from baseline to each visit where measured after re-treatment with ruxolitinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will recieve ruxolitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>All patients will recieve ruxolitinib</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status
             according to the 2008 revised International Standard Criteria

          -  Peripheral blast count &lt; 10%

          -  Requires therapy for MF in the opinion of the investigator

          -  Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive
             weeks and experienced treatment interruption because of lossof response or adverse
             event

          -  Patients adhering to the Screening phase assessments and undergoing a a
             ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks

          -  ECOG performance status 0, 1, 2, or 3

          -  Adequate bone marrow function

          -  Written informed consent

        Exclusion Criteria:

          -  Patients not initially responding (primary resistance) to ruxolitinib therapy

          -  Patients who underwent a splenectomy or spleen radiation

          -  Patients currently scheduled for bone marrow transplant

          -  Patients who have discontinued ruxolitinib &lt; 14 days prior to screening

          -  Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg
             total daily dose

          -  Leukemic transformation

          -  Inadequate renal function

          -  Presence of clinically meaningful active bacterial, fungal, parasitic or viral
             infection which requires therapy

          -  Previous history of Progressive Multifocal Leuko-encephalopathy (PML)

          -  Clinically significant cardiac disease or significant concurrent medical condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68305</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadanonda</city>
        <state>Madrid</state>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Myelofibrosis</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Myeloproliferative Disorders</keyword>
  <keyword>INC424</keyword>
  <keyword>Ruxolitinib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
